SCHEMBL11925795

SCHEMBL11925795

COc1cc(NC(=O)NCC(F)(F)F)cc(B2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.39
FGFR3 P22607 5/20 0.39
KDR P35968 3/20 0.39
NR1I2 O75469 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 2/20 0.38
EPHX2 P34913 1/20 0.38
RAB9A P51151 2/20 0.37
PKM P14618 1/20 0.37
MAPK1 P28482 1/20 0.37
CASR P41180 1/20 0.37
KMT2A Q03164 1/20 0.36
DGAT1 O75907 1/20 0.36
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
HSD17B10 Q99714 1/20 0.35
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10174975 0.89 MEN1 (0.47) L3MBTL1FGFR3KDRSMN1; SMN2RAB9A
SCHEMBL600503 0.88 FGFR4 (0.43) L3MBTL1FGFR3KDRNR1I2SMN1; SMN2
SCHEMBL11925794 0.85 L3MBTL1 (0.41) L3MBTL1FGFR3KDR
SCHEMBL15693723 0.82 L3MBTL1 (0.39) L3MBTL1FGFR3KDRSMN1; SMN2DGAT1
SCHEMBL73204 0.81 L3MBTL1 (0.50) L3MBTL1FGFR3KDR
SCHEMBL10225526 0.81 L3MBTL1 (0.38) L3MBTL1FGFR3KDRSMN1; SMN2
SCHEMBL15567289 0.80 L3MBTL1 (0.48) L3MBTL1KDRKMT2ADGAT1
SCHEMBL3319893 0.80 L3MBTL1 (0.52) L3MBTL1FGFR3KDRDGAT1
SCHEMBL30483059 0.80 SMN1; SMN2 (0.42) NR1I2SMN1; SMN2POLBRAB9AKMT2A
SCHEMBL10174972 0.76 FGFR3 (0.44) L3MBTL1FGFR3KDRSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2300465-B1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LTD (GB) 2019-04-17 EP disclosed
US-8796244-B2 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases ASTEX THERAPEUTICS LTD (GB) 2014-08-05 US disclosed
US-8796244-B2 Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases ASTEX THERAPEUTICS LTD (GB) 2014-08-05 US disclosed
US-20120208791-A1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-08-16 US disclosed
US-20120208791-A1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208791-A1 IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ABL1, ERBB2, RET L3MBTL1 4262/4885FGFR3 82/4885KDR 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.